Antibiotics biosynthesis findings a major advance in ‘superbug’ battle

Associate Professor Max Cryle
Associate Professor Max Cryle

New insights into antibiotics are vital in the quest to keep pace with the ever-evolving ‘superbugs’ that pose a serious threat to global public health. Recent research by Monash BDI scientist Associate Professor Max Cryle, published in Angewandte Chemie International Edition, represented a big step forward in the formation of a new glycopeptide antibiotic (GPA) to fight superbugs. GPAs are an important class of antibiotics, often used as the last resort against resistant bacteria.

The research attracted the attention of Retail Pharmacy Magazine, Australian Online News, MirageNews, Phys Org and the National Tribune. It shows for the first time how a wide range of new GPAs can be made by combining natural biosynthesis machinery and chemical modifications. This will enable the discovery and development of new antibiotics for clinical use – an avenue that is being rapidly pursued.